Novo Nordisk logoNovo Nordisk

Novo’s CagriSema was associated with 25% weight loss on average for women in a post hoc analysis of REDEFINE 1 presented at The Menopause Society Annual Meeting

Create this for my brand
Novo’s CagriSema was associated with 25% weight loss on average for women in a post hoc analysis of REDEFINE 1 presented at The Menopause Society Annual Meeting email from Novo Nordisk screenshot

Captured Announcement

Novo Nordisk press release announcing phase 3 REDEFINE 1 post hoc trial results of investigational CagriSema for weight loss in women across menopause stages.

Standard corporate press release layout featuring a top logo, bulleted key findings, narrative clinical paragraphs, unstyled data tables, and extensive reference footers.

Original email and brand assets belong to their respective owners. Design notes describe the creative, not campaign results.